Akorn buys rival generic drugmaker for $640 million
USA-based generics drugmaker Akorn (Nasdaq: AKRX) has bought rival generic drugmaker Hi-Tech Pharmacal (Nasdaq: HITK) for $640 million.
Akorn will pay $43.50 per Hi-Tech share, r.epresenting a premium of 23.5% percent to Hi-Tech's closing price on August 26. Akorn shares rose 13% to $18.52 in morning trading yesterday, after touching $18.98 for its biggest intraday increase since May 2010, noted Bloomberg. Hi-Tech increased 23% to $43.40
In a statement, Akorn said it expects to achieve between $15 million and $20 million in annual run-rate synergies within 12 months of closing the deal, which is expected in the fourth quarter. The combined company is expected to have annual revenues in excess of $500 million and the transaction is expected to be accretive to Akorn’s non-Generally Accepted Accounting Practice (GAAP) adjusted earnings per share immediately on closing.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze